<DOC>
	<DOCNO>NCT01389479</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerance immunogenicity Fluviral™ healthy adult age 18-64 year .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerance Immunogenicity Fluviral™ Healthy Adults</brief_title>
	<detailed_description>This study conduct ID BioMedical take GlaxoSmithKline . At time conduct study , Fluviral produce ID BioMedical .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Male female . Adults 1864 year age , inclusive . Satisfactory baseline medical assessment history , physical examination , clinical laboratory test . Capable informed consent . Able , willing likely fully comply study procedure restriction . Acute illness time enrollment . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection and/or chronic use immunosuppressant immunemodifying drug within 6 month administration study vaccine . Presence unstable chronic illness . Complicated diabetes mellitus . Active neurological disorder . History demyelinate disease include GuillainBarré syndrome . Any clinical laboratory abnormality . Any disorder coagulation treatment coumadin derivative heparin . Vital sign abnormality screen . Acute chronic liver , renal inflammatory bowel disease collagen vascular disease . Cancer , treatment cancer , within three year . History significant alcohol drug abuse within one year prior screen visit . Positive urine drug screen screen within 3 month prior screen visit hard drug . Products ativan , tylenol codeine stop sufficiently ahead screen visit order avoid positive urine drug screen . Positive test hepatitis B , hepatitis C human immunodeficiency virus screen . Receipt influenza vaccine within 9 month prior dose . Planned administration vaccine 30 day study immunization course study . Immunization emergency basis , Tetanus Diphtheria Toxoids Adsorbed adult use , allow provided vaccine administer within two week prior study immunization . Use investigational nonregistered drug vaccine participation investigational study within 30 day prior administration study vaccine , plan use study period . Receipt immunoglobulins and/or blood product within three month screen plan administration product study period . Receipt depot injection implant drug within 3 month prior administration study vaccine . Any known suspected allergy constituent Fluviral™ S/F Fluzone® . A history severe adverse reaction previous dose influenza vaccine . History anaphylactic type reaction consumption egg . Any condition social circumstance , opinion Principal Investigator , would make subject unsuitable unable complete study . Breastfeeding subject . Positive urine pregnancy test screening . Female subject sexual intercourse nonsterile male partner within 14 day prior vaccine administration without history acceptable contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>